First Manhattan CO Incyte Corp Transaction History

First Manhattan CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $34,546 - $39,426	-598 Reduced 99.67%	2 $0
Q2 2023 Aug 14, 2023	SELL	$60.95 - $75.51 $64,180 - $79,512	-1,053 Reduced 63.7%	600 $37,000
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $69,687 - $87,588	1,053 Added 175.5%	1,653 $125,000
Q2 2019 Aug 16, 2019	BUY	$73.52 - $88.7 $44,112 - $53,220	600 New	600 $50,000

705

189M

917K

459K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.